U.S. markets open in 9 hours 23 minutes
  • S&P Futures

    4,360.50
    -43.25 (-0.98%)
     
  • Dow Futures

    34,002.00
    -251.00 (-0.73%)
     
  • Nasdaq Futures

    14,318.50
    -182.50 (-1.26%)
     
  • Russell 2000 Futures

    2,007.90
    -23.80 (-1.17%)
     
  • Crude Oil

    83.64
    +0.33 (+0.40%)
     
  • Gold

    1,842.50
    +0.80 (+0.04%)
     
  • Silver

    23.84
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1325
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3481
    -0.0009 (-0.07%)
     
  • USD/JPY

    113.9060
    -0.0540 (-0.05%)
     
  • BTC-USD

    36,087.52
    +109.62 (+0.30%)
     
  • CMC Crypto 200

    821.53
    +10.93 (+1.35%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,113.13
    -475.24 (-1.72%)
     

Global COVID-19 Vaccines Industry

·25 min read

Abstract: After months of what seemed to be a receding pandemic supported by vaccines and adherence to new COVID appropriate protocols as the new normal, the world is witnessing the ghosts of the past rising once again.

New York, Jan. 14, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global COVID-19 Vaccines Industry" - https://www.reportlinker.com/p06097782/?utm_source=GNW
Barely months after the Indian strain called the Delta, or B.1.617.2 which was 40-60% more transmissible than Alpha and almost twice as transmissible as the original Wuhan strain of SARS-CoV-2 took over the world as a dominant strain, a new variant dubbed as "Omicron (B.1.1.529)" has emerged. Originally detected in South Africa in mid-November 2021, Omicron is now spreading across the globe with Asia, Europe, and North America reporting infections from this strain.

In addition to acquiring the mutations of the delta variant, the Omicron variant has over 50 mutations with 32 of them seen on its spike protein, two times higher than Delta, indicating that the virus has further adapted to the human species. Even more worrisome and unsettling is the fact that the variant also includes the vaccine-resistant alterations seen in Beta variant. The worst variant the pandemic has thrown up till date and carrying the mutations P681H and N679K, Omicron is feared to reduce vaccine effectiveness by close to 40% to 50%. There are fears that this strain is capable of outsmarting monoclonal antibodies, such as Regeneron`s treatment, since these therapies target parts of the virus that have now mutated. Currently classified as `variant of concern`, fears over the spreading Omicron have once again pushed countries across the globe to re-impose international and domestic travel restrictions. Omicron is now expected to displace the circulation Delta and other variants. It`s only a matter of time before a newer more competitive virus emerges. With Europe already battling fourth and fifth waves of infections, the new Omicron variant is bringing back ghosts of the past year. Fears are again rising over possible increase in infections, mortalities, overburdened hospitals, healthcare systems and lockdowns resulting in yet another economic nightmare. Lockdowns, travel and movement restrictions will be back once again if infection from this new strain fails to be controlled. India which is just recovering from the intense second wave with hopes of the disease reaching an endemic state, the new variant is reigniting fears of a possible third wave.

With several countries facing repeated waves of infections, the world is up against a new challenge in this war against the virus. An uphill challenge confronts governments in rapidly stepping up efforts to accelerate the pace of vaccine administration, despite numerous challenges. It`s a race against time and to successfully end the pandemic, mass vaccination drives must outpace the speed with which the coronavirus is currently mutating. After a sharp drop in cases throughout the second half of the year 2021, cases have begun to spike again led by infections from the Delta variant. This variant now accounts for the vast majority of new infections. With the rise in vaccination rates especially in developed countries, measures designed to limit the spread of Covid-19 like mask mandates and capacity limits have been relaxed. The subsequent relaxation strengthened consumer confidence and allowed economic activity to return to normalcy. However, with the Covid-19 virus rapidly mutating, new variants have emerged in many parts of the world, posing a threat of potential future waves. Different parts of Europe are currently witnessing fourth and fifth waves of infection spread. These new variants are more deadly than the original virus, more easily transmissible and can impact the effectiveness of vaccines.

Prolonging pandemic and new mutant strains means that immunity among vaccinated population is beginning to slip, throwing the focus on booster doses. The leading vaccine makers, Pfizer-BioNTech, Moderna and AstraZeneca announced plans to pursue development of booster shots to address the emerging threat of new virus variants. The booster shot will be essential to keep the immune system to the optimum level. A number of wealthy countries like the US, Germany and Israel are considering booster shots to increase protection against Covid-19. Germany is expected to roll out booster shots to vulnerable individuals. mRNA-vaccines from Pfizer/BioNTech and Moderna will be offered as booster shots, regardless of the vaccine administered previously. In India, Bharat Biotech, the makers of Covaxin, received regulator`s approval for conducting trials for a third shot that will be administered as a booster dose. While a booster dose is typically an exact replica of the initial vaccine, it can also be tweaked. Moderna, AstraZeneca, Pfizer are working on variant-specific booster shots. Recently, Moderna announced positive initial data from its ongoing phase 2 study.

The data revealed that the booster dose increased neutralizing antibody responses against the original virus as well as B.1.351 and P.1, in previously vaccinated individuals. Studies suggest that a third dose can boost antibodies even in immunocompromised patients. The rapid pace at which new strains capable of evading antibodies are rising is throwing the focus on vaccine tweaking and researchers are already working on updating vaccines with the new spike proteins to prepare for new variants with a new version of the vaccine. This however requires additional clinical trials, more time consuming research work, and regulatory approvals. The time-to-market remains a main challenge with the process taking six to eight months before vaccines can be updated and commercialized. This time-consuming development process is a major setback when compared to the rapid rate of infection spread from new strains.

In this race against virus evolution, swift and rapid vaccinations are the need of the hour to limit the spread of mutant strains, notwithstanding the fact that vaccines themselves are contributing to virus mutations. Rapid mass vaccinations will make the mutation process and threat more manageable. It is an undeniable fact that vaccines will see a slow erosion in efficacy and effectiveness over the long-term. Therefore it is important to slow the spread of the virus by vaccinating as many people as possible at the earliest. To end the pandemic, which currently seems to have received yet another setback will require more dedicated focus on vaccine equality, international cooperation in COVID research, more transparent information transfer and alert systems on new emerging strains, waiver of IP on vaccines, and science-based swift decisions regarding travel bans. All of these are vital to prevent squandering away "hard won gains" achieved against the virus over the last 2 years.


Select Competitors (Total 358 Featured)

  • Moderna, Inc.

  • Pfizer Inc./BioNTech

  • AstraZeneca/University of Oxford

  • Johnson & Johnson

  • CanSino Biologics, Inc.

  • China National Pharmaceutical Group Co., Ltd. (Sinopharm)

  • Sinovac Biotech Ltd.

  • Novavax, Inc.

  • Inovio Pharmaceuticals

  • Sanofi/GlaxoSmithKline

  • Gamaleya Institute




Read the full report: https://www.reportlinker.com/p06097782/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

COVID-19 VACCINE DEVELOPMENT - A GLOBAL MARKET OVERVIEW
Omicron Spreads Panic Worldwide; Omicron Variant Brings Back
Memories & Fears of the Worst Part of the 2020 Pandemic
EXHIBIT 1: Time is of Essence! What We Know So Far - ?Vaccine
Efficiency Against New Strains is Decreasing?
South Africa: Omicron?s Origin Location
Omicron: Impact on Travel Industry
Countries that have Already Detected Omicron Cases
Steps taken by the Countries to Prevent Transmission of Omicron
Variant
Fears of Tourism Industry
Industry Response to the Travel Curbs
Short-term Impact of Omicron on Travel
Financial Impact
Scientists Seek to Gather More Information on Omicron
Pharma Firms Aim to Improve Existing Vaccines to Counter Omicron
With New Strains Emerging at an Alarming Rate, Focus Shifts to
Booster Doses & Vaccine Tweaking. But How Practical Is It to
Implement Them?
EXHIBIT 2: With Vaccinated Population Showing Signs of
Declining Clinical Protection, Booster Doses Are Emerging Into
a Necessity to Restore Vaccine Effectiveness, but this
Strategy is Not Within Reach for Most Countries: Number of
Booster Doses Administered Per 100 People by Country as of
December 2021
At the Dawn of 2022, We Leave Behind Millions of Deaths Due to
New Strains & Once Again Stare at an Impending Catastrophe
Split Scenarios Unfold: The Great Vaccine Divide Emerges
Amid this Prolonged Pandemic, Why Should Businesses Care About
Progress on Vaccinations?
With IMF Making an Upward Revision of Global GDP for 2021,
Companies Are Bullish About an Economic Comeback Despite a
Continuing Pandemic
EXHIBIT 3: A Strong Yet Exceedingly Patchy & Uncertain Recovery
Shaped by New Variants Comes Into Play: World Economic Growth
Projections (Real GDP, Annual % Change) for 2020 through 2022
EXHIBIT 4: Easing Unemployment Levels in 2021 & 2022 Although
Moderate Will Infuse Hope for Industries Reliant on Consumer
Discretionary Incomes: Global Number of Unemployed People (In
Million) for Years 2019, 2020, 2021, and 2022
Widening Revenue Gap between mRNA COVID-19 Vaccines & their Rivals
COVID-19 Vaccine Makers Set to Reap Rich Dividends from Booster
Shots
Are COVID-19 Boosters Going to Follow Flu Shot Pattern?
Covid-19 Vaccine Shortages Hit Global Supply Initiative
Despite US Donation, Global Delivery of COVID-19 Vaccines
Remains Far Short of Target
Anti-Vaccine Movement Poses Significant Threat
EXHIBIT 5: COVID-19 Cases Worldwide by Country: As on November
21, 2021
EXHIBIT 6: COVID-19 Cases in the US by State: As on November
21, 2021

THE VARIOUS COVID-19 VIRUS VARIANTS
Emergence of Delta Variant Sparks New Wave of Infections
Is South African Variant a Formidable Threat?
E484K Mutation Challenges Vaccine Developers
California Strain Emerges to be more Contagious and Deadly
Is COVID-19 Virus Increasingly Resorting to Mutation to
Outsmart Vaccines?
Less Effectiveness of AstraZeneca Vaccine Against South African
Variant Leads to its Halt
Pfizer COVID-19 Vaccine Demonstrates Low to Modest Level of
Efficacy against South African Variant
US Government Unveils Covid-19 Vaccine Booster Shot Plan to
Maximize Vaccine Protection Against Emerging Variants
AstraZeneca Vaccine Effective against New Emerging Variants
Sinovac Vaccines Effective against Mutated Variants of Coronavirus

AN OVERVIEW OF COVID-19 VACCINE ROLLOUT
EXHIBIT 7: Roll-out Timeline of Select Frontrunners
COVID-19 Vaccine Approval Details
EXHIBIT 8: Production Capacity by Company for Frontrunners in
Millions of Doses for 2021
COVID-19 Vaccine Funding Details
Pfizer/BioNTech?s COVID-19 Vaccine Receives World?s First
Authorization
UK Clinches the First Position in the World to Approve Pfizer?s
Vaccine
After UK, Pfizer?s Vaccine Gains Approval from the US and EU
Novartis Inks Agreement with Pfizer-BioNTech to Support Covid-
19 Vaccine Production
After Pfizer, Moderna Vaccine Bags Coveted EUA from US FDA
Moderna Kick-Starts Inoculation in the US
AstraZeneca?s Vaccine - Third Globally to Obtain Approval
J&J?s Single Shot Vaccination Resumes After Temporary Suspension
Pfizer/BioNTech vs. Moderna vs. AstraZeneca vs. J&J Vaccine
A Comparison of Pfizer, Moderna, and AstraZeneca COVID-19 Vaccine
Johnson & Johnson’s Adenovirus-based COVID-19 Vaccine vis-a-vis
Moderna or Pfizer
Russia Commences Mass Vaccination from Mid-December, 2020
Russia?s Sputnik V Receives Approval for People Aged over 60
China Awards Conditional Approval to First COVID-19 Vaccine
from Sinopharm
WHO Approves China`s Sinopharm Covid-19 vaccine for Emergency Use
China Issues License for Vaccine Production to Overseas Partners
Brazilian Authorities Approve Sinovac?s CoronaVac
AstraZeneca?s Covishield and Bharat Biotech?s Covaxin Receive
Emergency Use Approval in India
Sanofi-GSK to Offer Vaccine at a Discounted Rate
CanSinoBIO Claims No Blood Clot Issues from COVID-19 Vaccine
Novavax Obtains First Authorization for its COVID-19 vaccine

VARIOUS COVID-19 VACCINES UNDER CLINICAL TRIALS
EXHIBIT 9: COVID-19 VACCINES UNDER DEVELOPMENT
EXHIBIT 10: COVID-19 Vaccine Candidates in Human Clinical Trials
EXHIBIT 11: Vaccines in Pipeline by Technology
EXHIBIT 12: Vaccine Technologies in Pre-Clinical Studies

mRNA: A NEW APPROACH TO MEDICINE
mRNA Vaccine Marks Dawn of New Era of Vaccines & Medical Therapies
RNA Technology: Benefits & Potential for Future Outbreaks
Key Challenges
mRNA Vaccines Could Vanquish COVID-19 and Cancer
Efforts to Target New Application Areas

MARKET DYNAMICS
Rise of Vaccine Passports: Key to Ease COVID-19 Restrictions &
Ensure Public Safety
Developments Regarding Digital Certificates
COVID-19 Vaccine Passport: Insights & Progress
Regions/Countries Planning to Seek Vaccine Passport
mRNA Vaccines Offer More Protection Against Newer Variants
Vaccine Companies Stress on Booster Dose
Longer Interval between the Two Doses of Pfizer Vaccine to
Boost Antibody Levels
Mix and Match is the New COVID-19 Vaccine Mantra
Long-Haul COVID-19 Holds Potential to Become a Public Health Issue
Vaccine Alliances Ensure Supplies for All
EXHIBIT 13: Select Funding Deals for COVID-19 Vaccine R&D: 2020 &
2021
Licensing and Partnership Deals Worldwide Propel Vaccine
Production
EXHIBIT 14: COVID-19 Deals Worldwide - Jan 2020 to July 2021

GLOBAL MARKET PERSPECTIVE
EXHIBIT 15: Global Percentage of Individuals Vaccinated by
Geographic Region - USA, Canada, Japan, China, Europe, Asia-
Pacific (India, Rest of Asia-Pacific), Latin America (Brazil,
Mexico, Rest of Latin America), Middle East and Africa
Markets - Independent Analysis of Percentage of Individuals
Vaccinated for 2020 through 2025
EXHIBIT 16: European Percentage of Individuals Vaccinated by
Geographic Region - France, Germany, United Kingdom, Italy,
Russia, Spain, and Rest of European Markets - Independent
Analysis of Percentage of Individuals Vaccinated for 2020
through 2025
EXHIBIT 17: Global Number of Annual COVID-19 Vaccine Doses (In
Million) for Years 2020 through 2025 by Geographic Region/
Country - USA, Canada, Japan, China, Europe, Asia-Pacific:
(India and Rest of Asia-Pacific), Latin America (Brazil,
Mexico, and Rest of Latin America), Middle East, and Africa
Markets
EXHIBIT 18: World 5-Year Perspective for COVID-19 Vaccines by
Geographic Region - Percentage Breakdown of Million Doses for
USA, Canada, Japan, China, Europe, Asia-Pacific (India and
Rest of Asia-Pacific), Latin America (Brazil, Mexico, and
Rest of Latin America), Middle East, and Africa Markets for
Years 2021 & 2025
EXHIBIT 19: World Current & Future Analysis for COVID-19
Vaccines by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific (India and Rest of Asia-Pacific), Latin
America (Brazil, Mexico, and Rest of Latin America), Middle
East, and Africa Markets - Independent Analysis of Annual
Doses in US$ Million for Years 2020 through 2025
EXHIBIT 20: World 5-Year Perspective for COVID-19 Vaccines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific (India and
Rest of Asia-Pacific), Latin America (Brazil, Mexico, and
Rest of Latin America), Middle East, and Africa Markets for
Years 2021 & 2025

VACCINES FOR KIDS
Kids: A Key to COVID-19 Controlling Efforts
US FDA Approves Pfizer-BioNTech Vaccine in Kids aged 5-11
Years, and 12 to 15 Years Age
Pfizer Approves Vaccine for Kids Aged 5-11 Years
Moderna Begins Testing its Vaccine on Children Aged Below 12
Years (March, 2021)
Oxford University Halts AstraZeneca COVID-19 Vaccine Trial on
Children over Perceived Safety Concerns
COVID-19 Vaccine Spikevax Approved for Children aged 12 to 17
in EU

REGIONAL MARKET PERSPECTIVE
THE UNITED STATES
Market Analysis
Current Vaccine Scenario
New Delta Variant Cases Cause Concern
Deceleration in Economic Activity Likely Due to Omicron Effect
US Recommends COVID-19 Booster Shots
Pfizer and Moderna?s COVID-19 Vaccine Secures US FDA?s
Emergency Use Approval for Booster Shot for Vaccinated Adults
US FDA Authorizes Johnson & Johnson?s COVID-19 Vaccine for
Booster Shot
Pfizer-BioNTech COVID-19 Vaccine Gets Emergency Use Nod in US
for Children 5-11 Years
US Regulators Give Nod to Pfizer-BioNTech COVID-19 Vaccine for
Ages 12 to 15
Moderna Aims to Achieve Approval for its COVID Vaccine for
Children
Reopening of Borders & Inflow of International Travelers to US
Spurs Demand for Digital Vaccine Certificates
Federal Health Agencies End Temporary Pause of J&J?s Covid-19
Vaccine Use
Sanofi Joins Hands with Moderna to Produce COVID-19 Vaccines
for Global Supply
The ?Operation Warp Speed? Program Expedites Vaccine Development
EXHIBIT 21: US Government Deals with Vaccine Developers
Market Analytics
EXHIBIT 22: USA Current & Future Analysis for COVID-19 Vaccines
Market: Annual Sales in Million Doses for the Years 2020
through 2025
EXHIBIT 23: USA Current & Future Analysis for COVID-19 Vaccines
Market: Annual Sales in US$ Million for the Years 2020 through
2025
CANADA
Market Analysis
Vaccination Gathers Steam across Canada
Canada Expands Approval for Pfizer-BioNTech & Moderna COVID-19
Vaccines to Cover Adolescents 12 Years & Above
Market Analytics
EXHIBIT 24: Canada Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in Million Doses for the Years
2020 through 2025
EXHIBIT 25: Canada Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in US$ Million for the Years
2020 through 2025
JAPAN
Market Analysis
Slow Rollout of COVID-19 Vaccines in Japan
Japan Ropes in Armed Forces to Expedite Vaccinations
Slow Vaccination Rates Affect Olympics
Japan Looks Forward to Double Supply of COVID-19 Vaccines to
Other Countries
Daiichi Sankyo Eyes on Booster Shots in Local Market for
Impending COVID-19 Vaccine
Vaccine Passports
Japan Inks Deal with Pfizer to Secure 50 Million Additional
Doses of COVID-19 Vaccine
Japan Pushes Shipments of Pfizer?s COVID-19 Shots to Vaccinate
Elderly
Takeda Obtains Approval for Moderna?s Vaccine
AnGes Fast Tracks COVID-19 Vaccine Development Program for 2021
Rollout
Japan Commences Production of AstraZeneca?s Vaccine
VLP Therapeutics Japan Commences Trial of Replicon RNA COVID-19
Vaccine
Market Analytics
EXHIBIT 26: Japanese Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in Million Doses for the Years
2020 through 2025
EXHIBIT 27: Japanese Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in US$ Million for the Years
2020 through 2025
CHINA
Market Analysis
Chinese Vaccine Development Scenario
China Reaches Milestone of Administering over Billion Covid-19
Vaccine Doses
Vaccine Candidates in China
CoronaVac from Sinovac Obtains Emergency Use Authorization in
China for Children
WHO Recognizes Sinopharm?s COVID-19 Jab as Effective & Safe
Chinese Regulator Gives Nod to COVID-19 Vaccine from Sinovac
Life Sciences
China Approves Sinopharm?s Vaccine
BioNTech?s Shot to Become First Western COVID-19 Vaccine to
Secure Authorization in China
Countries Relying on the Chinese COVID-19 Vaccines
Trials Indicate Neutralizing Effect of Chinese COVID-19
Vaccines on South African & UK Variants
Market Analytics
EXHIBIT 28: Chinese Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in Million Doses for the Years
2020 through 2025
EXHIBIT 29: Chinese Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in US$ Million for the Years
2020 through 2025
EUROPE
Covid-19 Scenario in Europe, Rise in Cases Noted
New Covid-19 Variants
Skepticism Regarding the Vaccination
Europe Witnesses Increase in COVID-19 Cases, Turns to Booster
Doses
EMA Approves Use of COVID-19 Vaccine of Pfizer for Children
EU to Recommend 9-MonthTime Limit for COVID-19 Vaccine Validity
for Travelers
EU Digital COVID Certificate Regulation to Aid Free Cross-
Border Movement
EU Digital COVID Certificate: Eligibility, Process & Free Movement
Pfizer & Moderna Escalate Unit Price of COVID-19 Vaccines in
Latest EU Contracts
EU Obtains 1.8 Billion Doses of Pfizer-BioNTech COVID-19 Vaccine
European Agency Makes Changes to Ramp Up Supply & Manufacturing
Capacity of Pfizer & Moderna COVID-19 Vaccines
BioNTech to Scale up Vaccine Production to Fill Supply Gaps and
Support Vaccination Efforts in the EU
Europe?s Horizon 2020
EC-AstraZeneca Settlement Deal Ends Legal Dispute over COVID-19
Vaccine Supplies
Johnson & Johnson to Resume Shipment of Janssen COVID-19
Vaccine to Europe
Apparent Side-Effects Prompt Denmark to Extend Suspension of
Oxford-AstraZeneca COVID-19 Vaccine
Market Analysis
UNITED KINGDOM
Vaccine Passport
UK Wins COVID-19 Vaccine Race with Approval of Pfizer-BioNTech
Vaccine
Vaccine Distribution Challenges
The UK Approves AstraZeneca?s Vaccine
Oxford-AstraZeneca?s COVID-19 Vaccine in the form of Nasal
Spray, to be Tested Soon (March, 2021)
Moderna Modifies Supply Contract with UK to Deliver Additional
Doses of COVID-19 Vaccine
UK?s Independent Vaccine Deals
GSK to Aid Production of Novavax?s COVID-19 Vaccine for
Distribution within UK
FRANCE
France Embarks on Plans to Offer COVID-19 Vaccine Free to Citizens
France Suggests mRNA Vaccines for Second Coronavirus Shot After
AstraZeneca?s First Shot
GERMANY
Germany Allows the Use of J&J Vaccine
SPAIN
Spain Prioritizes Frontline Healthcare Providers for
Immunization Policy
Spain to Donate Vaccines to Latin America and Caribbean
ITALY
Italy Plans to Produce mRNA Vaccines Domestically
RUSSIA
Gamaleya Institute?s Sputnik V Vaccine Trials Show Promise with
92% Efficacy
CanSino Obtains Approval for Phase III Trial of COVID-19
Vaccine in Russia
NORWAY
Norway Bans AstraZeneca COVID-19 Vaccine
Market Analytics
EXHIBIT 30: European Current & Future Analysis for COVID-19
Vaccines by Geographic Region - France, Germany, Italy, UK,
Spain, Russia, and Rest of European Markets - Independent
Analysis of Annual Doses in Millions for Years 2020 through
2025
EXHIBIT 31: European 5-Year Perspective for COVID-19 Vaccines
by Geographic Region - Percentage Breakdown of Million Doses
for France, Germany, Italy, UK, Spain, Russia, and Rest of
European Markets for Years 2020 & 2025
EXHIBIT 32: European Current & Future Analysis for COVID-19
Vaccines by Geographic Region - France, Germany, Italy, UK,
Spain, Russia, and Rest of European Markets - Independent
Analysis of Sales in US$ Million for Years 2020 through 2025
EXHIBIT 33: European 5-Year Perspective for COVID-19 Vaccines
by Geographic Region - Percentage Breakdown of Dollar Sales
for France, Germany, Italy, UK, Spain, Russia, and Rest of
European Markets for Years 2020 & 2025
ASIA-PACIFIC
Market Analysis
INDIA
Second Wave of Covid-19 in India Attributed to Delta Variant
Indian Government Initiates COVID-19 Vaccination Drive
India Makes Notable Contribution in Production of Vaccines
AstraZeneca?s Covishield Receives Emergency Use Approval in India
Spike in New Cases Coerces India to Briefly Suspend Export of
Oxford-AstraZeneca COVID-19 Vaccine
Bharat Biotech`s Covaxin Gets Approval
Bharat Biotech Obtains Government Financial Backing to Ramp up
Production of Covaxin
Panacea Biotec Obtains DCGI`s nod for Manufacturing Sputnik V
vaccine
Bharat Biotech & SII on Capacity Expansion Mode
Trial Indicates Decent Efficacy of Covaxin against B.1.617
Variant of COVID-19
IIL Partners with Bharat Biotech to Produce Active Drug
Substance for Covaxin
Johnson & Johnson?s Covid-19 vaccine, Produced by Biological E,
Ready for Export
Serum Institute Obtains Approval for Novavax Vaccine Trial in
7-11 Age Group
Increasing Commitments of SII and Novavax
Dr Reddy`s Rolls out Sputnik V Covid-19 Vaccine in India
DCGI Yet to Approve COVAXIN for Children
DCGI?s Approval Mandatory for the Covaxin to be Administered
for Children
Sanofi, GSK Obtains Approval to Conduct Phase 3 trial of their
Covid-19 vaccine in India
Zydus Vaccine Approved for Kids
AUSTRALIA
Australia to Invest On Novel Coronavirus Vaccines for Wider Region
NEW ZEALAND
New Zealand Acquires Ultra-Cold Freezers to Store Pfizer?s
COVID-19 Vaccine
SOUTH KOREA
With the Spread of Delta Plus Variant, Fresh Covid Cases
Witness a Sharp Increase
South Korea Extends its Vaccination Programme to the Workers of
Electronics and Chip Manufacturing Industries
J&J Covid-19 Vaccine Receives Approval in South Korea
INDONESIA
Indonesia Negotiates Additional COVID-19 Vaccines from China
and GAVI
Indonesia Gets First Consignment of COVID-19 Vaccine from
China?s Sinovac
Chinese Vaccine Sinovac Allowed for Use in Sri Lanka and
Bangladesh but restricted in Malaysia
BANGLADESH
Serum Institute of India to Offer 3 Crore Doses of COVID-19
Vaccine to Bangladesh
MYANMAR
China Meets Myanmar?s Requirements
Market Analytics
EXHIBIT 34: Asia-Pacific Current & Future Analysis for COVID-19
Vaccines by Geographic Region - Australia, India, New Zealand,
and Rest of Asia-Pacific Markets - Independent Analysis of
Annual Doses in Millions for Years 2020 through 2025
EXHIBIT 35: Asia-Pacific 5-Year Perspective for COVID-19
Vaccines by Geographic Region - Percentage Breakdown of
Million Doses for Australia, India, New Zealand, and Rest of
Asia-Pacific Markets for Years 2020 & 2025
EXHIBIT 36: Asia-Pacific Current & Future Analysis for COVID-19
Vaccines by Geographic Region - India, and Rest of Asia-
Pacific Markets - Independent Analysis of Dollar Sales in US$
Million for Years 2020 through 2025
EXHIBIT 37: Asia-Pacific 5-Year Perspective for COVID-19
Vaccines by Geographic Region - Percentage Breakdown of Dollar
Sales for Australia, India, New Zealand, and Rest of Asia-
Pacific Markets for Years 2020 & 2025
THE MIDDLE EAST
Market Analysis
BAHRAIN
Bahrain Becomes the Second Country to Offer Emergency Use
Approval to Pfizer?s Vaccine
Sinopharm?s Vaccine Doses Reach Bahrain
SAUDI ARABIA
COVID-19 Vaccine Production in the UAE
IRAN
Iran Procures Vaccine Doses
AFGHANISTAN
Afghanistan to Procure COVID-19 Vaccines
TURKEY
COVID-19 Vaccines in Turkey
ISRAEL
Israel Reimposes Restrictions
COVID-19 Vaccines for Israel
SYRIA
Syria Obtains AstraZeneca Vaccines, the first for the Country
Market Analytics
EXHIBIT 38: The Middle East Current & Future Analysis for
COVID-19 Vaccines Market: Annual Sales in Million Doses for
the Years 2020 through 2025
EXHIBIT 39: The Middle East Current & Future Analysis for
COVID-19 Vaccines Market: Annual Sales in US$ Million for the
Years 2020 through 2025
AFRICA
Market Analysis
UNICEF Enters into Agreement with Janssen Pharmaceutica for
Supply of Vaccine to African Union
Relief for Countries in Africa that Finally Receive Vaccine
Shipment as Third Wave Creates Havoc
Takeaways from Covid-19 Vaccine Program in Africa
SOUTH AFRICA
Approach of South Africa towards Covid-19 Vaccination Program
New Virus Variant in South Africa Creates a Challenge
South Africa Halts AstraZeneca?s Vaccination
Highly Infectious COVID-19 Variant Spurs Countries to Impose
Travel Ban from South Africa
South Africa: The First Country in Africa to Start Vaccine
Clinical Trial
South Africa to Resume J&J Jab Vaccination
Aspen to Manufacture Johnson & Johnson?s COVID-19 Vaccine in
South Africa
China to Deliver Potential COVID-19 Vaccine to Africa for Free
CEPI Identifies Biovac Institute as Potential Manufacturer in
South Africa
EGYPT
Market Analytics
EXHIBIT 40: African Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in Million Doses for the Years
2020 through 2025
EXHIBIT 41: African Current & Future Analysis for COVID-19
Vaccines Market: Annual Sales in US$ Million for the Years
2020 through 2025
LATIN AMERICA
Market Analysis
Mass COVID-19 Vaccination Campaigns Launched in Latin American
Countries
BRAZIL
Brazil Signs Deal to Buy Additional 100 Million Doses from
Pfizer/BioNTech
Brazilian Town Serrana Beats COVID-19 with China`s Sinovac Vaccine
Brazil, Turkey Announce Vaccination Plans for Chinese Vaccine
GSK to Aid Production of Novavax?s COVID-19 Vaccine for
Distribution within UK
Brazil Blocks Import of Russian Sputnik V COVID-19 Vaccine over
Efficacy & Safety Concerns
Covaxin Clinical Trial?s Stopped in Brazil but Supply Continued
in India
MEXICO
Mexico?s Cofepris Approves Emergency Use of Pfizer’s COVID-19
Vaccine
ARGENTINA
Argentina Secures 22 Million Doses of AstraZeneca?s COVID-19
Vaccine
CHILE AND PERU
Chile, Peru Approve Clinical Trials for AstraZeneca?s COVID-19
Vaccine
Chile Struggles with Escalating Cases of COVID-19 despite
Massive Rollout of Vaccine
CanSinoBIO Secures Emergency Use Authorization for COVID-19
Vaccine in Chile
MEXICO
Tulane University, Children?s Hospital Launch Moderna Covid-19
Vaccine Trial for Children
Market Analytics
EXHIBIT 42: Latin American Current & Future Analysis for COVID-19
Vaccines by Geographic Region - Brazil, Mexico, and Rest
of Latin American Markets - Independent Analysis of Annual
Doses in Millions for Years 2020 through 2025
EXHIBIT 43: Latin American 5-Year Perspective for COVID-19
Vaccines by Geographic Region - Percentage Breakdown of
Million Doses for Brazil, Mexico, and Rest of Latin American
Markets for Years 2020 & 2025
EXHIBIT 44: Latin American Current & Future Analysis for COVID-19
Vaccines by Geographic Region - Brazil, Mexico, and Rest
of Latin American Markets - Independent Analysis of Dollar
Sales in US$ Million for Years 2020 through 2025
EXHIBIT 45: Latin American 5-Year Perspective for COVID-19
Vaccines by Geographic Region - Percentage Breakdown of Dollar
Sales for Brazil, Mexico, and Rest of Latin American Markets
for Years 2020 & 2025

FOCUS ON THE FRONTRUNNERS
Moderna, Inc. (USA)
Pfizer Inc./BioNTech (US/Germany)
AstraZeneca/University of Oxford (The UK)
Johnson & Johnson (USA)
CanSino Biologics, Inc. (China)
China National Pharmaceutical Group Co., Ltd. (Sinopharm) (China)
Sinovac Biotech Ltd. (China)
Novavax, Inc. (USA)
Inovio Pharmaceuticals (USA)
Sanofi/GlaxoSmithKline (France/UK)

INITIATIVES FOR EQUITABLE DISTRIBUTION OF VACCINES
Fair Distribution of COVID-19 Vaccine
Vaccine Nationalism Hampers Equitable Distribution of Vaccines
COVAX Created to Ensure Fair and Universal Access to COVID-19
Vaccine
COVAX Inks Additional Deals for Global Rollout of COVID-19
Vaccines
African Countries Become Part of the COVAX Facility for Timely
Access to Successful Vaccines
COVAX Advance Market Commitment (AMC)
World Economic Forum to Push COVID-19 Vaccine Production
Capability
Pushing Manufacturing Capacity to Fulfil Global Demand
Technology Transfer and Other Payments

KEY VACCINE TECHNOLOGY PLATFORMS
Inactivated Vaccines
Inactivated Vaccine Candidate in Preclinical Development: As on
Nov 19, 2021
Protein-Subunit Vaccines
Protein-Subunit Vaccine Candidate in Preclinical Development:
As on Nov 19, 2021
Non-Replicating Viral-Vector
Non-Replicating Viral Vector Vaccine in Preclinical
Development: As on Nov 19, 2021
Replicating Viral Vector Vaccine Candidate in Preclinical
Development: As on Nov 19, 2021
Nucleic Acid Vaccines
RNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
DNA Vaccine Candidate in Preclinical Studies: As on Nov 19, 2021
Replicating Bacteria Vector
Live Attenuated Vaccines (LAVs)
Live Attenuated Virus Candidate in Preclinical Studies: As on
Nov 19, 2021
Live Attenuated Bacterial Vector Candidate in Preclinical
Studies: As on Nov 19, 2021
Virus-like Particle Vaccines
Virus-like Particles (VLP) Vaccine Candidate in Preclinical
Development: As on Nov 19, 2021

WORLD COVID-19 VACCINE BRANDS

SELECT CORPORATE DEVELOPMENTS IN THE COVID-19 VACCINE MARKET: 2021

III. COMPETITION
Total Companies Profiled: 358
Read the full report: https://www.reportlinker.com/p06097782/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001